Cartesian Therapeutics (RNAC) Equity Average (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Equity Average for 10 consecutive years, with -$81.0 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 2579.07% to -$81.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$81.0 million through Dec 2025, down 2579.07% year-over-year, with the annual reading at -$66.5 million for FY2025, 70.24% up from the prior year.
- Equity Average for Q4 2025 was -$81.0 million at Cartesian Therapeutics, down from -$19.2 million in the prior quarter.
- The five-year high for Equity Average was $89.4 million in Q4 2022, with the low at -$278.5 million in Q1 2024.
- Average Equity Average over 5 years is -$14.6 million, with a median of -$11.7 million recorded in 2021.
- The sharpest move saw Equity Average crashed 10166.94% in 2021, then soared 4615.96% in 2022.
- Over 5 years, Equity Average stood at $1.9 million in 2021, then skyrocketed by 4615.96% to $89.4 million in 2022, then crashed by 312.52% to -$189.9 million in 2023, then surged by 98.41% to -$3.0 million in 2024, then crashed by 2579.07% to -$81.0 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at -$81.0 million, -$19.2 million, and -$12.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.